Navigation Links
GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update
Date:11/6/2009

ATLANTA, Nov. 6 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) ("GeoVax" or "the Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2009 financial results and provided an operational update.

Robert McNally, Ph.D., President and Chief Executive Officer commented, "We are pleased with our progress during the third quarter of 2009 on several fronts. Enrollment for our Phase 2a preventative trial being conducted by the HVTN is proceeding according to plan. We are looking forward to a pre-IND meeting with the FDA later this year to discuss our plans for a Phase 1 therapeutic trial in early 2010. With a modest cash burn rate, continuing support from the HVTN, our IPCAVD grant from the NIH and with our common stock purchase agreement with Fusion Capital in place, our finances are in order to take us into 2011. As we move forward, we believe we will be in a strong position to seek additional government and private support for advancing both our preventative and therapeutic vaccines through Phase 2b and Phase 3 clinical trials."

"These are exciting times for GeoVax and everyone involved in HIV/AIDS vaccine development," Dr. McNally continued. "The recently announced success of a Thailand-based Phase 3 trial for an HIV/AIDS vaccine candidate owned by Sanofi-Aventis and Global Solutions for Infectious Diseases is encouraging to us all and has brought renewed interest to the field. At GeoVax, we have always been confident in our ability to develop an effective vaccine and this recent news has shown that a vaccine is indeed possible."

Review of Financial Results

The Company recorded a net loss of $230,815 for the three months ended September 30, 2009, compared to $722,108 for the same period in 2008. For the nine months ended Septem
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting
2. Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine
3. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
4. GeoVaxs Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
5. GeoVax Reports Progress on Its AIDS Vaccine Technology
6. GeoVax Secures $10 Million Financing Commitment
7. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
8. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
9. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
10. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
11. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Drug safety remains front and center for the U.S. ... improve the public,s perception of the organization. Likewise, the ... consumers and recognizes that its diligence in the reporting ... effort. One issue that is impacting both ...
... 28, 2011 VirtualScopics, Inc. (Nasdaq: VSCP ), ... announced that before the market opens on Thursday, February 24, ... 2010 financial results. The company will host a conference call ... President and Chief Executive Officer, Jeff Markin, and Chief Business ...
Cached Medicine Technology:Navigating the Gray Areas of Post-Marketing Surveillance 2VirtualScopics Schedules Fourth Quarter/Full Year 2010 Earnings Announcement 2
(Date:4/18/2014)... University psychologists have made a brain-related discovery that ... disorders. , This discovery opens up the possibility ... suppress a specific brain activity that the researchers ... The Journal of Neuroscience has just ... McDonald, an associate professor of psychology and his ...
(Date:4/17/2014)... non-cancerous prostate tissue may have nearly twice the risk ... inflammation, according to results of a new study led ... , The link between persistent inflammation and cancer was ... those with a Gleason score between 7 and ... and rapidly growing prostate cancers. , "What we,ve shown ...
(Date:4/17/2014)... of Experimental Biology and Medicine a ... and Paul Kenis in the Institute of Genomic ... of Illinois Urbana-Champaign describe their recent work on ... variety of cell functions including energy metabolism, signaling, ... in regulating normal cellular behavior, redox status has ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... ... ... ... ...
... ... ... ... ...
... compared traditional surgery with less-invasive stenting to clear dangerously ... "seminal and robust." The Carotid Revascularization Endarterectomy vs. ... of both procedures are roughly equal. The trial, conducted ... the largest randomized stroke prevention trials ever. Loyola ...
... ... Conducts Statewide Outreach Efforts to Provide Low-Income Children Access to Dental Care ... ... Month draws to a close, California’s dental hygienists are reminding parents and ...
... 12,000 years ago, researchers say, , FRIDAY, Feb. 26 (HealthDay ... East more than 12,000 years ago, new research suggests. , ... IGF1 is a major determinant of small size in dogs. ... domestication of the Middle Eastern gray wolf, according to the ...
... evidence that newcomers hold mettle against warfarin, aspirin , ... more proof that the mainstays of anti-clotting therapy, namely ... newcomers. , Researchers presenting their findings during a ... meeting in San Antonio show that one new drug, ...
Cached Medicine News:Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 2Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 3Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 4Health News:American National Announces Corrected Dividend Dates 2Health News:Stents as good as surgery for clogged carotid arteries 2Health News:California Dental Hygienists Say National Children's Dental Health Month Should Be a Yearlong Effort 2Health News:California Dental Hygienists Say National Children's Dental Health Month Should Be a Yearlong Effort 3Health News:Current Blood Thinners Face Tough Competition 2Health News:Current Blood Thinners Face Tough Competition 3
... of infrared laser photocoagulators includes the OcuLight ... lasers serve as a single laser source ... no regular maintenance or special electrical/cooling, and ... The OcuLight SLx is now available with ...
The simplest, most accurate Ortho-K lens fitting system ever!...
... permeable contact lenses used for corneal refractive ... (myopia). The patient wears the lenses overnight ... During the day, nearsightedness is corrected or ... RG contact lenses apply slight pressure to ...
MDI will work with your facility to determine the best interim lab to fit your needs and your site....
Medicine Products: